Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses
Background Shorter duration of symptoms before remdesivir has been associated with better outcomes. Our goal was to evaluate variables associated with the need of ICU admission in a cohort of hospitalized patients for COVID-19 under remdesivir including the period from symptoms onset to remdesivir. Methods We conducted a retrospective multicentric study analysing all patients admitted with COVID-19 in 9 Spanish hospitals who received treatment with remdesivir in October 2020. The main outcome was the need of ICU admission after 24 h of the first dose of remdesivir. Results In our cohort of 497 patients, the median of days from symptom onset to remdesivir was 5 days, and 70 of them (14.1%) were later admitted into ICU. The clinical outcomes associated with ICU admission were days from symptoms onset (5 vs. 6; p = 0.023), clinical signs of severe disease (respiratory rate, neutrophil count, ferritin levels and very-high mortality rate in SEIMC-Score) and the use of corticosteroids and anti-inflammatory drugs before ICU. The only variable significatively associated with risk reduction in the Cox-regression analyses was ≤ 5 days from symptoms onset to RDV (HR: 0.54, CI95%: 0.31–0.92; p = 0.024). Conclusion For patients admitted to the hospital with COVID-19, the prescription of remdesivir within 5 days from symptoms onset diminishes the need of ICU admission..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
---|---|
Enthalten in: |
BMC infectious diseases - 23(2023), 1 vom: 04. Mai |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Alonso-Navarro, Rodrigo [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
---|
Anmerkungen: |
© The Author(s) 2023 |
---|
doi: |
10.1186/s12879-023-08222-y |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2134822260 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | OLC2134822260 | ||
003 | DE-627 | ||
005 | 20230510163850.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230510s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12879-023-08222-y |2 doi | |
035 | |a (DE-627)OLC2134822260 | ||
035 | |a (DE-He213)s12879-023-08222-y-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
100 | 1 | |a Alonso-Navarro, Rodrigo |e verfasserin |4 aut | |
245 | 1 | 0 | |a Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s) 2023 | ||
520 | |a Background Shorter duration of symptoms before remdesivir has been associated with better outcomes. Our goal was to evaluate variables associated with the need of ICU admission in a cohort of hospitalized patients for COVID-19 under remdesivir including the period from symptoms onset to remdesivir. Methods We conducted a retrospective multicentric study analysing all patients admitted with COVID-19 in 9 Spanish hospitals who received treatment with remdesivir in October 2020. The main outcome was the need of ICU admission after 24 h of the first dose of remdesivir. Results In our cohort of 497 patients, the median of days from symptom onset to remdesivir was 5 days, and 70 of them (14.1%) were later admitted into ICU. The clinical outcomes associated with ICU admission were days from symptoms onset (5 vs. 6; p = 0.023), clinical signs of severe disease (respiratory rate, neutrophil count, ferritin levels and very-high mortality rate in SEIMC-Score) and the use of corticosteroids and anti-inflammatory drugs before ICU. The only variable significatively associated with risk reduction in the Cox-regression analyses was ≤ 5 days from symptoms onset to RDV (HR: 0.54, CI95%: 0.31–0.92; p = 0.024). Conclusion For patients admitted to the hospital with COVID-19, the prescription of remdesivir within 5 days from symptoms onset diminishes the need of ICU admission. | ||
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a Remdesivir | |
650 | 4 | |a Days from symptoms onset | |
650 | 4 | |a ICU | |
650 | 4 | |a Progression | |
700 | 1 | |a Ramírez, Margarita |4 aut | |
700 | 1 | |a Masiá, Mar |4 aut | |
700 | 1 | |a Paredes, Roger |4 aut | |
700 | 1 | |a Montejano, Rocío |4 aut | |
700 | 1 | |a Povar-Echeverria, Marina |4 aut | |
700 | 1 | |a Carratalà, Jordi |4 aut | |
700 | 1 | |a Salavert, Miguel |4 aut | |
700 | 1 | |a Bernal, Enrique |4 aut | |
700 | 1 | |a Dueñas, Carlos |4 aut | |
700 | 1 | |a Flores, Juan |4 aut | |
700 | 1 | |a Fanjul, Francisco |4 aut | |
700 | 1 | |a Gutiérrez, Isabel |4 aut | |
700 | 1 | |a Rico, Verónica |4 aut | |
700 | 1 | |a Mateu, Lourdes |4 aut | |
700 | 1 | |a Cadiñanos, Julen |4 aut | |
700 | 1 | |a Berenguer, Juan |4 aut | |
700 | 1 | |a Soriano, Alex |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BMC infectious diseases |d BioMed Central, 2001 |g 23(2023), 1 vom: 04. Mai |h Online-Ressource |w (DE-627)326645381 |w (DE-600)2041550-3 |w (DE-576)107014793 |x 1471-2334 |7 nnns |
773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:04 |g month:05 |
856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12879-023-08222-y |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2007 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2031 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2056 | ||
912 | |a GBV_ILN_2057 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2113 | ||
912 | |a GBV_ILN_2134 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_2446 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 23 |j 2023 |e 1 |b 04 |c 05 |